The type of genetic testing which is employed to diagnose or predict the gene mutation or genetic changes linked to a disease is called predictive genetic testing. It is usually used in a symptomatic person to check future risks. The branch of genomics concerned with the sequencing and interpretation of the individual is called consumer genomics, while the one which predicts the genetic factors contributing to healthy living is called wellness genomics. This type of testing enables a person to make good lifestyle changes and choices.
The rising health care awareness and shifting population preference toward a healthy lifestyle have led to the expansion of the market for predictive genetics testing & consumer/wellness genomics. Factors such as the rising attention of the government and other private regulatory bodies toward public health care, increased effectiveness & quality of genetic testing, prevalence of chronic diseases & genetic diseases such as Parkinson’s & cystic fibrosis are expected to drive the global predictive genetics testing & consumer genomics market during the forecast period. Furthermore, the rising need to understand one’s family history is propelling the global market as well. However, stringent regulatory rules and ethics for the approval of genetic testing could limit the market’s development through 2025.
In terms of test type, the global predictive genetics testing & consumer/wellness genomics market can be categorized into the predictive testing, consumer genomics, and wellness genomics segments. Predictive testing can be further divided into the genetic susceptibility testing, predictive diagnostic, and population screening sub-segments. On the basis of application, the global market can be split into the following groups: cancer screening, cardiovascular screening, musculoskeletal screening, diabetic screening, Parkinson’s / Alzheimer disease screening, and others.
Geographically, the global predictive genetics testing & consumer/wellness genomics market is distributed over North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America held a major market share, followed by Europe. The dominance of North America can be ascribed to to factors such as its well-established health care infrastructure, high awareness level, prevalence of chronic diseases, and high adoption of new technologies. However, Asia Pacific is anticipated to grow at a significant rate due to the growing population, rise in disposable income, increasing demand for genetic testing, prevalence of unhealthy lifestyles, and mounting government intervention in the development of health care infrastructure. Also, the market in this region has been observed to be targeted by multiple established players, as countries such as China and India are projected to be favorable markets for new entrants in the wellness genomics sector.
Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=24473
Most players in the predictive genetics testing & consumer/wellness genomics market are focused on developing technologically advanced and cost-efficient services in order to offer comfortable, easy, and quicker testing solutions to customers. To gain a significant position in the global predictive genetics testing & consumer/wellness genomics market, these companies adopt various policies including strategic alliances, forward & backward integration, new product development, and mergers & acquisitions. For instance, several pharmaceutical industries are entering into partnerships with genomic companies, diagnostic laboratories, and government organizations. Intermountain Healthcare and Syapse announced a collaboration in May 2014, which enables oncologists to access different technologies related to cancer genomics.
Key players operating in the global predictive genetics testing & consumer/wellness genomics market include ARUP Laboratories, Genesis Genetics, Pathway Genomics, Color Genomics Inc., BGI, and Myriad Genetics, Inc.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
Despite its vendor landscape being highly consolidated, intense rivalry prevails among key players in the global autoimmune disease diagnostics market. According to Transparency Market Research (TMR), the top four companies held over 50% of the global autoimmune disease diagnostics market in 2014. Among the leading enterprises, F. Hoffmann-La Roche Ltd. held the dominant share of over 17% in the market in the same year.
In response to the increasing demand for effective and advanced autoimmune diseases diagnosis, TMR expects the competition among rivals to surge further. Furthermore, the market demonstrates considerable scope for new entrants. The rising demand for novel and improved autoimmune diagnostics will pave the way for the entry of new players in the market. Contrary to this, competitive pricing, rising R&D investments, and shortening product lifecycles may restrict the entry of new players.
This 80 page report gives readers a comprehensive overview of the autoimmune disease diagnostics market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/autoimmune-disease-diagnostics-market.html
Increased Prevalence of Autoimmune Diseases a High-impact Driver
Autoimmune diseases affect millions around the world, which makes precise diagnosis extremely important. As per a lead TMR analyst, “The globally increasing incidence of autoimmune diseases is bolstering the demand for autoimmune disease diagnostics globally.”
Governments across both developed and developing nations are exploring efficient diagnosis and therapeutic options to prevent the spread of chronic ailments. This, combined with the rising healthcare spending across emerging nations, will augur well for the autoimmune disease diagnostics market in the forthcoming years. As per the TMR analyst, “The latest technological advancements witnessed in the healthcare sector will further set the tone for the market’s expansion.”
People around the world have become more aware about the prevalence of various autoimmune diseases. This not only encourages them to adopt preventive measures, but creates demand for autoimmune disease diagnostics in case of the occurrence of the disease. This increasing awareness has led to the rising demand for autoimmune diseases diagnostics globally.
Competitive Pricing Strategies by Players Could Hamper Profit Margins
Due to the prevailing competition and threat from local enterprises, the leading market players are compelled to maintain competitive pricing. This could have an adverse impact on the market’s overall growth prospects as the rising competition will slash prices of products. The market is also threatened by the lack of skilled professionals. The unavailability of trained professionals and inadequate automation create operational challenges in clinical laboratories. This could hamper the market’s trajectory in the forthcoming years.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving autoimmune disease diagnostics market during 2015 – 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=5351
Companies Looking to Capitalize on Opportunities in Asia Pacific to Expand their Footprint
The future of the autoimmune disease diagnostics market looks promising with multinational companies capitalizing on the opportunities mushrooming in the emerging economies of Asia. Besides this, the companies are also focusing on automating laboratories and replacing conventional technologies. The advent of novel technologies holds lucrative opportunities for the market’s future.
By disease type, rheumatoid arthritis accounted for the largest share in the market in 2014. The segment is expected to remain the dominant segment surging at 4.2% CAGR between 2015 and 2023. Regionally, North America led the global autoimmune disease diagnostics market in 2014 with a share of 39%.
As per TMR, the global autoimmune disease diagnostics market stood at US$12.3 bn in 2014. Rising at a CAGR of 3.8%, the market is expected to reach US$17.06 bn by the end of 2023.
The global intravenous immunoglobulin (IVIG) market is largely consolidated, with top four players: Grifols S.A., CSL Behring LLC, Baxalta Incorporated, and Octapharma AG, accounting for over 70% of the overall market in 2015. Grifols S.A. accounted for the dominant share of 23.0%, chiefly on account of the company’s strong geographic penetration.
Oligopoly in the market has led to intense competition among top players and has compelled companies to take course of strategic mergers and acquisitions and geographic expansions. Point in case is the CSL Behring LLC’s geographic expansion by opening operations in Russia in December 2015. The company stated that the expansion was driven by large unmet need of quality biotherapeutics and blood plasma products in the country.
This 155 page report gives readers a comprehensive overview of the intravenous immunoglobulin (IVIG) market. Browse through 18 data tables and 56 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/intravenous-immunoglobulin-market.html
Transparency Market Research estimates that the global intravenous immunoglobulin (IVIG) market, which was valued at US$7.23 bn in 2015, is projected to expand at a CAGR of 8.5% from 2016 to 2024 and reach US$14.92 bn in 2024. In terms of end users, the hospitals segment is presently leading, accounting for a more than 62% of the overall market in 2015. The segment is, however, expected to lose prominence to the home care segment and reflect a loss in its overall share by 2024. In terms of geography, North America, which presently accounts for over 45% of the global market, is expected to retain dominance by 2024 as well.
Rising Prevalence of Neurological Diseases to Boost Global Demand for IVIG Products
The rapidly rising prevalence of a variety of hematological and neurological disorders such as alloimmune thrombocytopenia, idiopathic thrombocytopenic purpura (ITP), and myasthenia gravis is the chief factor driving the intravenous immunoglobulin (IVIG) market. For instance, the occurrence of myasthenia gravis in the U.S. has been assessed at 14 to 20 cases out of 100,000 people, which comes to around 36,000 to 60,000 cases in the country. This neuromuscular transmission has a high probability of remaining undiagnosed and thus the prevalence of this disease is actually much higher. Over 40% of the world’s IVIG products are used to treat neurological diseases, thus the rising prevalence of neurological disorders is a highly significant factor of growth for the global IVIG market.
Moreover, the mounting global population of geriatrics, which is more vulnerable to diseases due to poor immunity, is also a key factor driving the IVIG market. According to the WHO, the global geriatric population is expected to increase from 524 mn in 2010 to 1.5 bn by 2050. This is anticipated to drive the increased demand for better immunological treatments, which in turn would provide opportunities for companies operating in the global intravenous immunoglobulin market. The steady rise in the use of intravenous immunoglobulin for the treatment of off-label indications a significant rise in the blood plasma yield across the globe are also likely to drive the intravenous immunoglobulin (IVIG) products market.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving intravenous immunoglobulin (IVIG) market during 2016 – 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1930
High Cost of Treatment and Potential Side Effects to Hamper Market Growth
One of the key challenges that could hamper the overall development of the global IVIG market is the comparatively much higher cost of plasma collection and manufacturing processes as compared to conventional pharmaceutical manufacturing and processing products. Moreover, immunoglobulin products being derivatives of blood, they require highly sophisticated methods and equipment for collection, purification, and storage. This scenario adds to the overall cost and complexity of IVIG products and therapies.
Intravenous immunoglobulin (IVIG) preparations also have several related side effects, which could lead to serious health problems in some patients. Owing to this, patients are sometimes discouraged from continuing IVIG therapies. Side effects associated with the use of IVIG also sometimes encourage clinicians to opt for alternate therapies. This factor is likely to restrain the overall development of the intravenous immunoglobulin (IVIG) market in the next few years.
This review of the market is based on a recent market research report published by Transparency Market Research, titled “Intravenous Immunoglobulin (IVIG) Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024.”
The leading players in the global healthcare information systems market are Cerner Corporation, McKesson, and All Scripts. Collectively, these players held a share of 26% in the global market in 2015, states Transparency Market Research. The diversified portfolio of these companies is expected to help them maintain a lead in the coming years. Several companies in the global healthcare information systems market are expected to focus on increasing geographical presence through mergers and acquisitions to increase their revenues.
According to the research report, the global healthcare information systems market is expected to reach a valuation of US$448 bn by the end of 2024 as compared to US$192 bn in 2015. During the forecast years of 2016 and 2024, the global market is expected to expand at a CAGR of 10.1%.
This 226 page report gives readers a comprehensive overview of the healthcare information systems market. Browse through 48 data tables and 69 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/healthcare-information-system.html
North America Poised to Acquire a Share of 36.6% by 2024
The end users in the global market are hospitals, academic and research centers, and diagnostic centers. The report indicates that hospitals are expected to key users of healthcare information systems by the end of 2024. This end-user segment is projected to expand at a CAGR of 11.1% between 2016 and 2024. The increasing adoption of healthcare information systems in hospitals for storing a large amount of information and making it easily accessible to physicians is expected to boost the demand.
In terms of geography, the global healthcare information systems market is segmented into North America, Latin America, the Middle East and Africa, Asia Pacific, and Europe. Of all these regions, North America is expected to dominate the global market in the coming years. This regional market is slated to acquire a share of 36.6% in the overall market by the end of 2024. Asia Pacific too is expected to offer the healthcare information systems market a significant boost in the near future.
Need to Reduce Errors and Costs Ensures Swift Uptake of Healthcare Information Systems
Request a sample of this report to know what opportunities will emerge in the rapidly evolving healthcare information systems market during 2016 – 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1457
Growing number of government initiatives to digitize healthcare systems has led to the adoption of healthcare information systems. These systems are aimed at achieving an accurate analysis of the health of the patient by maintaining the records about patient’s disorders or diseases in an organized manner. Over the years, the usage of healthcare information systems has allowed improved the quality of medical assistance provided to the patients along with improving disease surveillance. These systems have also enabled reduction of medication error. The market for healthcare information systems is also expected to be fueled by the growing need to cut down on healthcare costs that are associated with paperwork and maintenance of physical records.
High Cost of Investments and Maintenance Likely to Discourage Growth of Global Market
The high cost of investments in such as purchasing the systems, installing them, and the cost training labor to use them is discouraging many end users from adoption the new-age healthcare information systems. The maintenance cost of these systems includes software upgradation, hardware replacement, and support. Thus, all of these factors are acting as a major restraint for the global market. The report also points that concerns pertaining to cyber security are also likely to hamper the growth of the overall market in the coming years. Lastly, issues related to integration and interoperability are also likely to hold the market back to a noticeable extent.
This review is based on Transparency Market Research’s report, titled “Healthcare Information Systems Market – Global & North America Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024.”
Prefilled Syringes Market: Snapshot
Parenteral is one of the most commonly used route of drug administration, oral administration being the most preferred one. A steady rise in the development and availability of parenteral drugs has resulted in the increasing demand for several advanced drug delivery devices that promise cost containment as well as ease of administration.
Prefilled syringes are one of the most rapidly expanding segments of the injectable drug delivery devices market. There are several benefits of prefilled syringes over traditional delivery systems: improved safety, ease of administration, accurate dosing, and reduced risk of contamination. These advantages form the basic foundation for the success of prefilled syringes and are likely to continue driving the market during the forecast period.
Technical advances in the sector, rapid growth in the biologics market, and the growing preference for self-administration using autoinjectors, prefilled syringes, and pen injectors are the key factors boosting the global market for prefilled syringes.
The global sales of prefilled syringes amounted to US$3.5 bn in 2015 and is projected to reach US$7.9 bn, expanding at a CAGR of 9.3% over the period of 2016 to 2024.
This 187 page report gives readers a comprehensive overview of the prefilled syringes market. Browse through 24 data tables and 104 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/prefilled-syringes-market.html
Glass Prefilled Syringes to Lose Market Share Despite being Most Preferred Segment
Prefilled syringes are available in two key types – plastic (polymer) and glass – depending on the kind of material used to develop the barrel of the syringe. Despite the fact that the industry has been reporting a growing use of polymers by many manufacturers of syringes, glass is still considered to be the top-most choice and will continue to dominate the market in terms of volume as well as revenue. This is attributed to the fact that changing the perception of healthcare practitioners and manufacturers over the preference of glass over plastic is expected to be a rather gradual process. The segment of glass prefilled syringes is anticipated to lose market share toward the end of the forecast period, which will be replaced by plastic syringes. The latter is expected to grow at a CAGR of 10.8% from 2016 to 2024.
By application, the market is segmented into vaccines, monoclonal antibodies, and others. On the basis of distribution channel, the prefilled syringes market is categorized into hospitals, ambulatory surgical centers, and mail order pharmacies.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving prefilled syringes market during 2016 – 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1131
Japan Most Promising Market in APAC Prefilled Syringes Market
Europe has maintained its position as the leading regional market for prefilled syringes in terms of volume (unit consumption) as well as revenue. However, the APAC market for prefilled syringes is anticipated to exhibit strong growth at a CAGR of 11.3% during the forecast period. The presence of leading drug manufacturers in the region requiring prefillable syringes and the high conversion rate from vials to prefilled syringes are the primary factors likely to support the growth of the APAC market.
Asia Pacific is perceived as a follower rather than a leader when it comes to the development and adoption of new technologies. Although the prefilled syringes market is presently in its stage of infancy in APAC, factors such as improving economic conditions, the rising purchasing power of the people, the growth in awareness regarding the advantages of prefilled syringes, and the presence of a large patient suffering from various chronic diseases are expected to drive the market to register a double-digit CAGR. In Asia Pacific, Japan accounts for the major share in the market by revenue as well as volume.
Major players in the global prefilled syringes market include Becton Dickinson & Co., Gerresheimer, Medtronic, Baxter International, SCHOTT AG, West Pharmaceuticals, Vetter International, Unilife Corporation, Stevanato Group, and Terumo Corporation.